Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PRTO

Proteon Therapeutics (PRTO) Stock Price, News & Analysis

Proteon Therapeutics logo

About Proteon Therapeutics Stock (NASDAQ:PRTO)

Advanced Chart

Key Stats

Today's Range
$5.65
$6.15
50-Day Range
$0.84
$25.13
52-Week Range
$0.22
$3.94
Volume
562,713 shs
Average Volume
1.11 million shs
Market Capitalization
$136.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Receive PRTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRTO Stock News Headlines

ProQR Therapeutics price target raised to $4 from $2.50 at Chardan
Last time you’ll see this priced at $1.00
When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!
ProQR Announces Major Share Offering Agreement
See More Headlines

PRTO Stock Analysis - Frequently Asked Questions

Proteon Therapeutics Inc (NASDAQ:PRTO) released its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that Proteon Therapeutics investors own include Bristol-Myers Squibb (BMY), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), ImmunoGen (IMGN), Onconova Therapeutics (ONTX), Sierra Oncology (SRRA) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Last Earnings
10/31/2019
Today
1/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTO
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

Net Income
$-20,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.06) per share

Miscellaneous

Free Float
N/A
Market Cap
$136.18 million
Optionable
Not Optionable
Beta
0.60
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PRTO) was last updated on 1/6/2025 by MarketBeat.com Staff
From Our Partners